Merus to Participate in Upcoming Investor Conferences
01 November 2023 - 11:00PM
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company
developing innovative, full-length multispecific antibodies
(Biclonics® and Triclonics®), today announced that Bill Lundberg,
M.D., President, Chief Executive Officer of Merus, will participate
in the following investor conferences:
- BMO Biopharma Spotlight Series:
Oncology Day (fireside chat): Wednesday, November 8 at 11:30-11:55
a.m. ET (No live webcast, replay will be available after the
event)
- Stifel 2023 Healthcare Conference
(fireside chat): Tuesday, November 14 at 1:15-1:45 p.m. ET (Live
webcast available contemporaneously)
Archived presentations will also be available on the Investors
page of the Company's website for a limited time after the
event.
About MerusMerus is a
clinical-stage oncology company developing innovative full-length
human bispecific and trispecific antibody therapeutics,
referred to as Multiclonics®. Multiclonics® are manufactured
using industry standard processes and have been observed in
preclinical and clinical studies to have several of the same
features of conventional human monoclonal antibodies, such as long
half-life and low immunogenicity. For additional information,
please visit Merus’ website and twitter.
Multiclonics®, Biclonics® and Triclonics® are registered
trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl
Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From Apr 2024 to May 2024
Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From May 2023 to May 2024